Month: December 2025

香港, 2025年12月12日 - (亚太商讯 via SeaPRwire.com) - 12月11日，中国领先的工业供应链技术与服务提供商 - 京东工业（股份代号：7618.HK）正式登陆香港联合交易所。作为工业供应链领域的标杆企业，京东工业的上市不仅是自身发展的里程碑，更为港股市场注入了一支兼具成长力与盈利能力的优质目标。数智化重构价值 财务表现彰显成长实力作为行业领军者，京东工业以数智化能力重构工业供应链价值。公司通过「太璞」这一「数」（数智）、「实」（商品）结合的全链路数智化工业供应链解决方案，提供广泛的工业品供应和数智化供应链服务，精准匹配客户的多元化需求，实现供应链效率与成本控制的双重提升。财务数据是京东工业成长潜力的最直接印证。近年来，公司业绩呈现“高增长、高盈利”的双优态势，持续经营业务总收入从2022年的人民币（下同）141亿元，稳步增长至2023年的173亿元，2024年进一步攀升至204亿元，复合年增长率高达20.1%；盈利能力更实现高速稳健增长，2022年，公司录得经调整净利润7.1亿元，而2024年大幅攀升至9.1亿元，展现出强劲的盈利转化能力。2025年上半年，公司业绩持续释放，期内公司实现持续经营业务总收入103亿元，经调整净利润达5.0亿元，较上年同期保持高速增长，在复杂的市场环境中展现出稳健的盈利能力与可持续的增长潜力。品牌生态相互协同 构筑行业龙头地位强大的品牌影响力和供应链能力为京东工业的发展奠定了坚实基础。依托JD.com的深厚积淀，公司自成立以来便建立起良好的品牌认可度。值得一提的是，JD.com在2025年《财富》世界500强榜单中位列第44位，作为中国领先的在线零售商，其在商品质量与正品保障上的严苛标准，早已成为电商行业的标杆。借助这一优质品牌背书，京东工业成功渗透至多个垂直行业的高价值客户群体，不仅构建了广泛的品牌认知，更深化了客户忠诚度。京东生态系统的协同效应更成为公司的核心竞争力之一。京东工业全面继承并持续复用京东集团在供应链领域的核心优势，包括一流的技术研发平台、深耕行业的产品知识储备、覆盖全国的完善物流服务网络，以及专业的人才梯队，这些资源的协同赋能，推动公司在技术创新与服务升级上不断突破。多重优势迭加持下，京东工业已确立稳固的行业龙头地位。截至目前，公司已成为中国MRO采购服务市场的最大参与者，根据灼识咨询的数据显示，按2024年的交易额计，公司排名第一，规模为第二名的近三倍。同时，随着业务向全工业供应链领域拓展，公司亦以4.1%的市场份额，成为中国工业供应链技术与服务市场的领军企业。总体而言，京东工业凭借数智化核心能力、稳健的财务表现及强大的品牌与生态协同优势，在工业供应链这一高增长赛道上构建了深厚壁垒。此次登陆港交所，不仅为公司搭建起更为广阔的资本运作平台，更标志着其开启了与全球投资者共享发展红利的新征程。展望未来，随着中国工业数字化转型的加速推进，京东工业的增长空间有望持续拓宽，长期投资价值值得期待。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年12月12日 - (亚太商讯 via SeaPRwire.com) - 12月10日，京东工业股份有限公司（「京东工业」或「公司」，股份代号：7618.HK）正式公布全球发售配发结果。公司最终发售价格确定为每股14.10港元，香港公开发售部分反响热烈，实现60.52倍超额认购，共接收超过7万份有效申请，最终发售数目为21,121,000股，占全球发售股份总数的约10%；国际配售部分同样表现亮眼，超额认购倍数约为7.88倍。双重超额认购的市场反馈，充分彰显了全球投资者对京东工业商业模式与发展潜力的高度认可。全链条解决方案铸就领先地位 端到端数智化基础设施赋能庞大客户群作为中国领先的工业供应链技术与服务提供商，京东工业以「太璞」全链路数智化解决方案为核心竞争力，构建起「数」（数智）+「实」（商品）深度融合的服务体系，为企业客户提供覆盖广泛的工业品供应及数智化供应链服务。通过这一体系，公司能够有效满足客户在保供、降本、增效及合规等多维度需求，推动工业供应链领域的数字化变革。凭借深厚的行业积淀，京东工业确立了市场领先地位，已成为中国MRO采购服务市场的最大参与者，根据灼识咨询的数据显示，按2024年的交易额计，公司不仅是中国MRO采购服务市场的龙头企业，规模接近第二名的三倍，同时也是中国工业供应链技术与服务市场的最大服务提供商，市场份额达4.1%，行业标杆地位凸显。这一地位的背后，是京东工业构建的端到端数智化基础设施。基于服务千万企业客户的实战经验，公司打造的「太璞」解决方案，实现了「数」（数智）与「实」（商品）相结合，通过将数智化能力深度赋能客户，引领企业采购供应链的数智化转型。其核心价值在于践行「让数据多跑路，让商品少跑路」的理念，使供需对接更顺畅、匹配更精准、协同更高效，从根本上提升工业供应链的整体韧性与敏捷度。二十余年京东集团供应链管理经验的传承，为京东工业积淀了深厚的专业知识储备。在此基础上，公司不断迭代自身的供应链专业知识，在产品、客户、垂直行业及供货商等领域实现突破，形成了强大的综合竞争力。根据灼识咨询的资料，截至2024年12月31日，公司的SKU数量冠绝中国工业供应链技术与服务市场；截至2025年6月30日，SKU数量已增至约8110万个，2025年6月30日前十二个月内服务重点企业客户约11100个。高客户粘性进一步印证其服务价值，2024年重点企业客户交易额存留率达105.7%，充分体现了客户对其服务的高度信赖与持续认可。收入与盈利高速增长 数字化浪潮助力打开增长空间受益于行业数字化转型浪潮及自身核心能力的持续释放，京东工业近年来业绩实现稳步增长。公司持续经营业务总收入从2022年的人民币（下同）141亿元，增长至2023年的173亿元，2024年进一步攀升至204亿元，复合年增长率达20.1%；从半年期数据看，截至2025年6月30日止六个月，公司持续经营业务总收入达103亿元，较上年同期实现显著增长。同时，公司盈利能力同步实现快速提升，2022年，公司录得经调整净利润7.1亿元，而2024年已大幅攀升至9.1亿元，2025年上半年，公司延续高增长态势，经调整净利润达5.0亿元，较上年同期保持高速增长，展现出强劲的盈利韧性与增长持续性。关于募集资金的用途，京东工业在招股书中已作出明确披露：约35%的募集资金净额计划在未来48至60个月内用于于进一步增强公司的工业供应链能力；约25%的资金净额将投入跨地域业务扩张；约30%的资金净额预留用于潜在战略投资或收购；剩余约10%的资金净额则将用于一般公司用途及补充营运资金，为整体业务的平稳运行筑牢保障。一系列清晰详实的资金规划，既锚定了业务的持续升级与稳健扩张方向，亦彰显出公司强劲的发展活力与健康向好的经营态势。从行业角度来看，中国工业供应链市场的数字化渗透率目前仍处于较低水平，存在巨大的提升空间，根据灼识咨询的数据显示，中国工业供应链市场的数字化渗透率在2024年仅为6.2%，预计到2029年将达到8.2%。数字化渗透率的提高预计将推动工业供应链技术与服务市场规模快速增长，由2024年的人民币0.7万亿元增至2029年的人民币1.1万亿元，复合年增长率达到9.8%，广阔的市场空间为京东工业提供了充足的增长动能。京东工业作为工业供应链数智化转型的领航者，既拥有技术赋能的核心优势，又具备市场领先的规模效应，更手握行业增长的时代机遇。凭借独特的业务模式、覆盖全链路的服务能力及持续迭代的创新实力，在港上市后，公司将持续拓展服务边界与深度，长期增长潜力巨大，有望在实现自身持续成长的同时，为投资者创造长期、稳定的价值回报。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年12月12日 - (亚太商讯 via SeaPRwire.com) - 在产业升级、数智化转型加速及政策支持等多重因素驱动下，工业供应链技术正迎来爆发式发展期。作为行业公认的领军企业，京东工业（7618.HK）凭借深厚的技术积淀与全链条服务能力，于12月11日成功登陆港交所，为工业供应链板块注入一枚优质目标，开启发展新征程。数智驱动筑牢壁垒 全链能力构建核心竞争优势作为中国领先的工业供应链技术与服务提供商，京东工业以数智化转型为核心抓手，致力于为客户打造保供、降本、增效及合规的全场景解决方案。公司构建了端到端的供应链数智化基础设施，并通过公司广泛的商品供应、卓越的服务与高效的运营，精准破解工业供应链领域诸多共性痛点，构筑了强大的核心竞争力。基于这套核心基础设施打造的「太璞」解决方案，是京东工业「数」（数智）、「实」（商品）结合的全链路数智化工业供应链的标杆成果，同时，公司采用了轻资产模式搭建高效且可扩展的业务，并通过「太璞」为各行业、各规模的客户提供跨场景、跨品类的全面工业品供应以及技术与服务，真正实现「大小客户全覆盖、全场景需求全满足」。独特的价值创造模式为京东工业积累了广泛且优质的客户基础。根据灼识咨询的数据显示，截至2025年6月30日前的十二个月内，公司服务约11100个重点企业客户。2025年上半年，公司的重点企业客户包括约60%的中国《财富》500强企业及逾40%的在华全球《财富》500强企业，充分印证了市场对其服务能力的高度认可。商品供给能力的广度与深度，是京东工业的另一核心竞争力。根据灼识咨询的数据显示，截至2024年底，按SKU数量计，公司在中国提供最广泛的工业品供应。具体数据方面，截至2025年6月30日，京东工业提供的工业品SKU数量已达约8110万个，全面覆盖80个核心产品类别。截至2025年6月30日前的十二个月内，公司的商品供应源自于由约158000家制造商、分销商及代理商组成的广泛的且覆盖全国的工业品供应网络，彰显强劲综合实力。业绩增长强劲 上市募资锚定长远发展优质的客户结构与高效的运营模式，推动京东工业的业绩实现持续高增长。2022年至2024年，公司持续经营业务总收入从人民币（下同）141亿元稳步增长至204亿元，复合年增长率高达20.1%；盈利能力同步提升，经调整净利润从2022年的7.1亿元大幅攀升至2024年的9.1亿元。2025年上半年，公司延续高增长态势，持续经营业务总收入达103亿元，经调整净利润为5.0亿元，成长韧性凸显。对于本次上市的募集资金用途，京东工业已制定清晰规划：约35%将在未来48至60个月内用于强化核心供应链能力，进一步夯实技术与服务壁垒；约25%将投入跨地域业务扩张，拓展市场覆盖边界；约30%预留用于潜在战略投资或收购，加速生态整合；剩余约10%则用于补充营运资金及一般公司用途。这套「强核心、扩边界、筑生态」的资金规划，为公司长远健康发展提供了坚实保障。综合来看，京东工业凭借数智化技术优势、全链路服务能力、广泛的客户基础及持续的增长潜力，在工业供应链升级浪潮中占据了显著的先发优势。此次成功登陆港交所，不仅是公司发展的重要里程碑，更将为其后续成长注入强劲动力。作为工业供应链数智化转型的领军者，公司的长期投资价值已然凸显，未来有望在产业升级进程中持续释放增长活力。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年12月12日 - (亚太商讯 via SeaPRwire.com) - 中国领先的文旅服务企业 – 印象大红袍股份有限公司（新三板股票代码：870608）（「公司」或「印象大红袍」）今日宣布启动香港公开发售计划（「香港公开发售」），计划于香港联合交易所有限公司（「香港联交所」）主板上市（股份代号：2695）。发售详情印象大红袍拟全球发售合共36,100,000股股份（视乎超额配股权行使与否而定 ），其中32,490,000股作国际配售（可予重新分配及视乎超额配股权行使与否而定），其余3,610,000股作香港公开发售，分别位全球发售中发售股份总数的90%及10%售（可予重新分配及视乎超额配股权行使与否而定 ），发售价范围介乎每股3.47港元至4.10港元。香港公开发售将于2025年12月12日（星期五）上午九时正开始，至2025年12月17日（星期三）中午十二时结束。最终发售价及配发结果将于2025年12月19日（星期五）公布。股份预计将于2025年12月22日（星期一）在联交所主板以每手买卖单位为1,000股开始买卖，股份代号为2695。公司拟将全球募集资金净额用于以下用途：升级标志性演出《印象‧大红袍》山水实景演出；创新印象文旅小镇；取得另一个文化旅游演出项目；提升品牌形象及扩大业务影响力的宣传工作；升级票务管理系统及其他软件；营运资金和其他一般企业用途。兴证国际融资有限公司及铠盛资本有限公司为联席保荐人。公司主要竞争优势拥有《印象‧ 大红袍》的独家演出权 成功经验具可复制性公司的标志性《印象‧ 大红袍》山水实景演出在福建省乃至全中国都拥有强势的行业地位。根据弗若斯特沙利文的资料，于2024年，该演出按票房收入计在中国所有旅游山水实景演出中排名第三。公司背靠强大的股东背景和合作资源，取得《印象‧ 大红袍》的独家表演权，这种独家性为公司提供了显著的竞争优势，使公司成为中国旅游山水实景演出市场及文旅演出市场的无可争议的市场领导者。《印象‧ 大红袍》演出以武夷山的自然景色为背景，提供绝美的视觉体验，同时得益于其被联合国教科文组织认可的地理位置，武夷山同时拥有文化和自然遗产。这优越的地理优势与便利的交通相辅相成，结合航空、高速公路和高速铁路的现代化多维交通网络，为国内外游客提供便捷的交通，为公司实现收入增长。《印象‧ 大红袍》的成功经历，使公司积累了深厚的文化故事叙述、观众互动以及运营卓越的认知，为打造下一款全新节目《月映武夷》奠定重要的成功基石。《月映武夷》演出于2025 年5 月推出，丰富了武夷山市观看表演演出的选择，并提供完全不同的戏剧文化体验。该演出弘扬武夷山朱子文化的传统中国哲学，表演舞台拥有关键的技术特色，被誉为「世界最大的单体结构室内水帘舞台」，已于2025 年5 月1 日获世界记录认证公司(World Record Certification Limited) 认证。此部新演出与《印象‧ 大红袍》山水实景演出形成互补。品牌效应和政府政策背书 建立领先的市场地位福建省拥有丰富的自然景观和深厚的文化底蕴，当地政府努力增加武夷山与其他主要枢纽城市之间的航班和铁路连接，并分配资源促进旅游业发展。福建现场演出市场于2023 年及2024 年分别实现了约485.9%及67.5%的同比增长率。随着福建作为中国文旅枢纽的声誉不断提升，省政府进一步突出「文旅演出+」的概念，促进融合当地文化和标志性文物景点。公司作为一直深耕福建省武夷山的领先文旅服务企业，《印象‧ 大红袍》的成功经历和利好的政府政策背书，充足的文化资源为演出创作者提供丰富的灵感源泉。公司凭借福建省悠久的文化遗产和多样的地理风貌的优势，使其旅游演出具有潜力、可创造高影响力的价值，成为该地区文旅市场的推手。核心服务联动 强大协同效应目前公司通过演出及表演服务（《印象‧ 大红袍》及《月映武夷》）、印象文旅小镇业务及茶汤酒店业务，产生协同效应，提升整体游客的体验，并加强公司在当地文化旅游市场的竞争优势。公司战略性地开发的印象文旅小镇，主要由武夷茶博园4A级景区、印象建州美食主题街区和武夷茶研习社组成。为了延长游客观看演出前的消费链，公司把小镇打造为集「美食餐饮+ 民俗文化+ 商业购物+ 休闲娱乐」于一体。为了丰富游客的体验并扩大公司的业务范围，公司建立的茶汤酒店业务于2021 年盛大开业，其提供以茶为主题的热浴养生体验，将大红袍茶的元素无缝融入宾客的服务之中。整合运营围绕武夷山大红袍茶，为公司的三大业务板块带来了协同效应。通过整合核心服务组合，公司向武夷山市的游客提供全面的一站式旅行体验。游客可探索印象文旅小镇，感受当地的茶文化，观看现场演出，并入住独特的主题茶汤酒店。多样活动不仅丰富了游客的体验，亦延长了游客在武夷山的逗留时间，增加了每位游客的消费额。随着业务组合的稳步扩大，业务之间的协同潜力可形成良性循环，推动长期稳定增长。提示本次发售将会受到市场和其他条件影响，因此无法保证是否可成功完成发行及完成时间，实际发行规模和具体条件也可能发生变化。本新闻稿仅为印象大红袍股份有限公司首次公开募股相关信息之目的而提供，并不构成对该证券的出售要约或购买要约或邀请。也不得在任何国家或其他司法管辖区中要约或出售该证券。如果依据该国家或其他司法管辖的证券法，在注册或取得资格前进行此种出售要约、要约购买或销售为非法。本新闻稿并不构成招股章程（包括根据香港法律所定义者），潜在投资者在决定是否投资于公司前，务请细阅公司招股章程内有关公司及建议发售的详细资料。本新闻稿并未经港交所或香港证券及期货事务监察委员会审阅或批准。公司股价可能根据香港法例第571W章「证券及期货（稳定价格）规则」进入稳定期，有关价格稳定详情及其将如何受到香港法例第571W章「证券及期货（稳定价格）规则」已在公司于2025年12月12日刊发之招股章程中披露。关于印象大红袍股份有限公司印象大红袍股份有限公司（新三板股票代码：870608）是一家国有文旅服务企业，并于2017年于中国新三板挂牌完成上市。公司业务主要业务分部：(i)演出及表演服务；(ii)印象文旅小镇业务；及(iii)茶汤酒店业务。其中，公司的标志性节目《印象‧大红袍》山水实景演出作为公司的业务的基石，是唯一一个联合国教科文组织世界自然和文化遗产地内进行的现场演出，也是唯一一个与中国传统茶文化历史交织的大型户外实景演出。于2024 年，《印象‧大红袍》按票房收入计在中国所有旅游山水实景演出中排名第三，在所有文化旅游演出中排名第十1。按文旅演出节目产生的销售收入计，公司在2024年中国文旅演出市场排名第八1。1根据弗若斯特沙利文的资料本新闻稿由亿万猴财经传讯有限公司代表印象大红袍股份有限公司发布。联系方式：Sabrina / Christopher电话：9464 8907 / 5592 6231电邮：sabrinawong@bmonkey.com.hk / christopher@bmonkey.com.hk Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, December 11, 2025 - (ACN Newswire via SeaPRwire.com) – Hong Kong’s exports are expected to grow by between 8% and 9% in 2026, according to figures releaased today by the Hong Kong Trade Development Council (HKTDC). The forecast forms part of the HKTDC’s annual Export Outlook report and follows on from the city’s better-than-anticipated 2025 export performance.For 2026, this sustained growth is set to be driven by robust demand for AI-related electronics products. According to the findings of the recently-released HKTDC 4Q25 Export Confidence Index, the majority of exporters (53.2%) see rising demand for AI/new technology-related electronic consumer goods as the factor most likely to boost their 2026 business. This is seen as crucial given that the electronics sector, overall, accounts for more than 70% of Hong Kong’s total export value.Heightened uncertainty giving way to greater clarityThese upbeat figures are remarkable given the high year-on-year comparison base from 2025. This is because many exporters sought to frontload orders in a bid to complete shipments before the imposition of the much-anticipated US tariffs.Detailing the upshot of the tariff-related trade upheavals in particular, Irina Fan, Director of HKTDC Research, said: “While 2025 proved to be a year of heightened uncertainty, 2026 should be a year of greater clarity on global trade. With the Chinese Mainland and the US having come to a trade agreement in November, – some four months after many other nations had struck their own deals with the Trump administration – US tariffs are no longer among Hong Kong exporters' three biggest 2026 concerns.”Fan did, however, acknowledge that uncertainties remain ahead. She said that as US imports from different countries are subject to different levels of tariffs, business leaders around the world will be looking to re-organise their activities to optimise any cost advantages.Outlining what this will mean within the Asia-Pacific region, Fan said: “Chinese Mainland exports to the US will be subject to 20% reciprocal tariff rate until November 2026 [1]. This comparatively low additional tariff puts China-based suppliers, many with more mature and highly productive supply chains, on par with their Southeast Asia counterparts, while giving them a significant advantage over any country subject to a higher tariff rate.”Multi-sector expectation of continued export expansionUnderpinning Hong Kong’s anticipated 2026 export expansion are the findings of the HKTDC Export Confidence Index 4Q25, which was also released today. The two key measures of this long-established quarterly metric –the Current Performance Index (51.4) and the Expectation Index (51.9) – have both stayed above the 50-point watershed level, a clear indication that future export growth is expected.Commenting on the findings of the 4Q25 survey, Kenneth Lee, Head of the HKTDC Research’s Special Project and Business Advisory Section, said: “When it comes to expansion plans over the next two-year period, Asia remains very much the focus. For 42.0% of respondents, the Chinese Mainland was the highest priority market, followed by the rest of Asia (30.3%) and the ASEAN bloc (18.9%). By industry, exporters in almost every sector saw scaling up their activities on the Chinese Mainland as their priority.”Beyond the headline findings of the survey, a more detailed analysis highlights good news for Hong Kong exporters in terms of both individual market prospects and the likely future success of most of the city’s key industry sectors.Positive sentiments for major markets and key industry sectorsIn specific terms, turning to the Market Expectation Sub-Index, the Chinese Mainland (57.2) and the ASEAN bloc (57.0) are still considered to have significant growth potential. Predictably, this was less the case for the US (down 1.4 to 38.0), with the uncertainties in its trade environment continuing to unsettle Hong Kong exporters.Turning to individual industries, a number of sectors have expansionary expectations for the year ahead (i.e. had a relevant index reading of 50 or more). Topping the list is Jewellery (54.8), followed by Electronics (52.4), Timepieces (51.6) and Equipment/Materials (51.1).Despite such overall positive sentiments, the survey also points out the possibility that a number of challenges may lie ahead. Most notably, it cited rising labour and production costs (53.9%), growing logistics challenges (38.8%) and declining overseas orders on account of the general economic slowdown (38.2%) as potential future concerns.[1] On top of Trump 1.0 tariffs of ~20% on averageReferencesHong Kong 2026 Export Outlook: Sustained AI Product Demand Set to Drive 8-9% Growth Over Coming Year:https://research.hktdc.com/en/article/MjE4ODc2Mzk2NwHKTDC Export Confidence Index 4Q25: End-of-Year Figures Indicate Positive Expansion Prospects:https://research.hktdc.com/en/article/MjE4ODYyNTQwNwHKTDC Research website: https://research.hktdc.com/en/ Photo download: https://bit.ly/4oJPrPRHKTDC Director of Research Irina Fan (right) and HKTDC Section Head, Special Project & Business Advisory, Kenneth Lee (left) announced the HKTDC Export Confidence Index for 2025’s fourth quarter at a press conference todayHKTDC Director of Research Irina FanHKTDC Section Head, Special Project & Business Advisory Kenneth LeeMedia enquiriesPlease contact the HKTDC’s Communication and Public Affairs Department:Navin LawTel: (852) 2584 4525Email: navin.cm.law@hktdc.orgAgnes WatTel: (852) 2584 4554Email: agnes.ky.wat@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, December 12, 2025 - (ACN Newswire via SeaPRwire.com) – Everest Medicines announced on Dec. 11, 2025 that its wholly-owned subsidiary, Everest Medicines (China) Co., Ltd (“Everest Medicines China”), has entered into two strategic agreements with privately held Hasten Biopharmaceutical Co., Ltd. (“Hasten”). The first is a Commercialization Services Agreement leveraging Everest's existing sales and marketing organization to provide commercialization services for a portfolio of Hasten's mature assets.The second is a License Agreement granting Everest the exclusive license to develop, register and commercialize Lerodalcibep, a novel, small protein-binding, third-generation PCSK9 inhibitor, which is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH) in Greater China.The two agreements are expected to create significant financial and strategic synergies, enhancing the operational efficiency of Everest’s existing commercial platform and accelerating the build-out of life-cycle and multi-channel commercialization capabilities. At the same time, they establish an attractive strategic footprint for the Company in the cardiovascular disease area. Through this collaboration, Everest will further strengthen its commercial foundation in China, expand market share, and inject core momentum into the long-term growth of its cardiovascular business. The potential approval of Lerodalcibep in Greater China in 2027 is expected to contribute to future revenue growth within Everest's cardiovascular portfolio.Commercialization Synergies to Strengthen Competitiveness Across a Multi-Product PortfolioEverest Medicines China will receive service fees from Hasten calculated by multiplying the net sales of each product for the applicable quarter by the applicable rate, which ranges from 20% to 55%. The proposed maximum annual caps for the transactions contemplated to be paid by Hasten for the three years ending December 31, 2028 are set at RMB 560 million in 2026, RMB 616 million in 2027, and RMB 677 million in 2028.The Commercialization Service Agreement covers six mature, commercially available products across three major therapeutic areas—critical care, cardiovascular disease, and metabolic disorders—including Rocephin(R), Stilamin(R), and Ebrantil(R) in critical care; Edarbi(R) and Blopress(R) in cardiovascular disease; and Basen(R) in metabolic disease. The portfolio is highly synergistic with Everest’s existing commercial infrastructure and strategic focus. Among them, the three core critical care products—Rocephin(R), Stilamin(R), and Ebrantil(R)—play an essential clinical role in the treatment of infectious, gastrointestinal emergency, and cardiovascular emergency conditions. Rocephin(R), for example, is a broad-spectrum, third-generation cephalosporin that has achieved coverage in more than 8,500 hospitals nationwide and holds over 80% market share, maintaining strong and sustained clinical demand in the treatment of complex infections. Notably, these transactions are expected to generate significant synergies for Everest by aligning XERAVA(R) with Hasten’s critical care portfolio — including Rocephin(R) and Stilamin(R) — across complementary geographic footprints, channel access and hospital coverage, while further strengthening the Company’s commercialization capabilities and life-cycle management of innovative medicines.With the addition of this product portfolio, the Company’s commercial presence in key therapeutic areas such as critical care and cardiovascular diseases will be further expanded, creating stronger synergies with its existing commercialization organization and providing more robust support for the scaled development and revenue growth of its commercial platform.Introduction of Lerodalcibep to Expand Strategic Footprint in Cardiovascular DiseasesThe agreement grants Everest the exclusive license to develop, register and commercialize Lerodalcibep in Greater China, together with a royalty-free, exclusive license to use Hasten's trademarks for the product in the territory. Pursuant to the license agreement, Everest Medicines China will make an initial payment of US$29 million (approximately RMB 205 million), and may pay up to US$30 million (RMB 212 million) in potential development and regulatory milestone payments and up to US$280 million (RMB1977 million) in potential sales milestones, in addition to royalties based on the total, aggregate annual net sales.Lerodalcibep, developed by privately-held and U.S.-based company LIB Therapeutics, is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Lerodalcibep is a novel, small protein-binding, third-generation PCSK9 inhibitor, and has been developed as a more patient friendly and convenient, once-monthly, single small-volume, subcutaneous injection that will not require refrigeration at home or in travel. These features make Lerodalcibep a unique alternative to approved PCSK9 inhibitors. In large, global phase 3 clinical trials in over 2,500 patients, Lerodalcibep has demonstrated sustained LDL-C reductions of >60% in patients with, or at very-high or high risk of, cardiovascular disease (CVD) and >55% in those with heterozygous familial hypercholesterolemia (FH) who have more severe LDL-C elevations. In addition, the head-to-head LIBerate-VI study, comparing Lerodalcibep with Inclisiran, demonstrated the superiority of Lerodalcibep (p=0.0319). Lerodalcibep is expected to expand treatment options for the millions of patients around the world with CVD, including the 30 million individuals with FH. These LDL-C reductions have been confirmed in a recent phase 3 clinical trial in a Chinese population with, or at very high risk of, CVD including FH.Multiple PCSK9 inhibitors are currently approved and marketed in China, with a combined market size of approximately RMB 3 billion and year-over-year revenue growth of 95% in 2024. The market is expected to further increase to approximately RMB10 billion in 2030, according to a Frost & Sullivan report. Despite an estimated 400 million individuals in China with dyslipidemia, only ~14% receive lipid-lowering treatment, reflecting low penetration and significant unmet medical need. Lerodalcibep has patent exclusivity in China through 2039.Lerodalcibep is currently under regulatory review by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In Greater China, Biologics License Application (BLA) submission is expected in 1H 2026, with the potential for approval in 2027.Everest considers Lerodalcibep an important future growth driver and a key addition to its innovative medicines portfolio. The transaction is viewed as aligned with the Company’s strategy to focus on high-potential therapeutic areas and to expand its late-stage pipeline through business development collaborations, thereby strengthening its overall portfolio.Market commentators note that the two agreements provide both near-term revenue contribution and clear longer-term growth opportunities. By leveraging its established medical, market access, marketing and sales capabilities, Everest is expected to improve the efficiency of its commercial operations and resource utilization, while further demonstrating the scalability and resilience of its commercial platform. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com